

Addressing the Global Threat of Antimicrobial Resistance (AMR)

As the world's largest manufacturer of antibiotics, Teva is committed to working with industry peers and global health organizations to identify solutions.

Our approach to addressing AMR focuses on:

- Research and science
- Access
- Appropriate use
- Environment



Drug-resistant infections kill 700,000 people each year, including 230,000 from multidrug-resistant tuberculosis.¹

This could increase to 10 million deaths each year by 2050 if no action is taken.¹

Teva is the leading provider of many medicines listed on the World Health Organization's (WHO) Essential Medicines List (EML), which includes important medicines for addressing key healthcare needs.

We manufacture
45%
of antibiotics/
anti-infectives on
the WHO's EML²



Promoting access to critical antibiotic and antifungal medicines for those in need through qualified donation partners and global health tenders



Serving on board of AMR Industry Alliance, which brings together 100+ biotech, diagnostics, generics and research-based pharmaceutical companies to drive progress to reduce AMR



Helped develop AMR Industry Alliance's Antibiotic Discharge Targets, referred to as Predicted No-Effect Concentrations, for environmental risk assessments of antibiotics



Published Teva's position on AMR, detailing our commitment, approach and aspirations for tackling this global challenge



Developed materials and tools for Teva's markets to increase awareness of AMR and encourage appropriate use



Developed 35+ generic antibiotics and antifungals, 20+ of which target WHO priority pathogens

1. World Health Organization (WHO), 2019. No time to wait: Securing the future from drug-resistant infections. Report to the Secretary-General of the United Nations.

2. WHO, 2021, WHO Essential Medicine List, 22nd List 2021